This vaccination schedule elicited robust T cell responses to 29mer peptides encoding SIINFEKL, as well as mutant Spas1, a well characterized tumor neoantigen from the TRAMP-C2 tumor model[57] (S1 Fig). Here, SPATA19 is linked to neoplasm.